

PI Major Mutations:None

PI Accessory Mutations:None

PR Other Mutations:I13V 100%  
seen1851 • E35D 100%  
seen1827 • M36I 99%  
seen1827 • R41K 99%  
seen1881 • R57K 99%  
seen1827 • D60E 99%  
seen1881 • L63P 100%  
seen1827 • H69K 100%  
seen1834 • L89M 100%  
seen1851

Protease Inhibitors	
atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
fosamprenavir/r (FPV/r)	Susceptible
indinavir/r (IDV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible
nelfinavir (NFV)	Susceptible
saquinavir/r (SQV/r)	Susceptible
tipranavir/r (TPV/r)	Susceptible

No drug resistance mutations were found for PI.

NRTI Mutations:None

NNRTI Mutations:[E138A](#) 99%  
seen1212

RT Other Mutations:V8I 100%  
seen1271 • V35T 99%  
seen1281 • V60I 100%  
seen1282 • D121H 100%  
seen1238 • K122E 99%  
seen1238 • I135T 100%  
seen1267 • I142V 99%  
seen1274 • K173L 99%  
seen1267 • Q174K 100%  
seen1267 • V179I 100%  
seen1271 • I202V 100%  
seen1271 • Q207A 100%  
seen1267 • R211S 99%  
seen1281 • E248D 100%  
seen1282 • K277R 100%  
seen1288 • T286A 100%  
seen1273 • I293V 99%  
seen1281 • P294T 99%  
seen1281 • E312T 100%  
seen180 • V314M 100%  
seen180

Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible	doravirine (DOR)	Susceptible
zidovudine (AZT)	Susceptible	efavirenz (EFV)	Susceptible
stavudine (D4T)	Susceptible	etravirine (ETR)	Potential Low-Level Resistance
didanosine (DDI)	Susceptible	nevirapine (NVP)	Susceptible
emtricitabine (FTC)	Susceptible	rilpivirine (RPV)	Low-Level Resistance
lamivudine (3TC)	Susceptible		
tenofovir (TDF)	Susceptible		

RT comments

NNRTI

- E138A is a common polymorphic accessory mutation weakly selected in persons receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. Its effect on ETR- and RPV-containing regimens is likely to be minimal.

Other

- V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.
- This virus is predicted to have low-level reduced susceptibility to **RPV**. The use of the combination of CAB/**RPV** should be considered to be relatively contraindicated.

No drug resistance mutations were found for NRTI.

Drug resistance mutation scores of NNRTI:

Download CSV

Rule	DOR ⚖	EFV ⚖	ETR ⚖	NVP ⚖	RPV ⚖
<a href="#">E138A</a>	0	0	10	0	15